Michael Francis was named CEO of Gap's largest brand amid intensifying market competition, alongside developments involving Eli Lilly and Novo Nordisk.

The entities involved

• Michael Francis →

  researcher (ORCID 0000-0002-5430-0661)

  Nothing else this week.

• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08

Related events

• Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Sep 14
• Gap Inc. confirmed its banner operations and appointed Michael Francis to lead a brand reinvigoration effort.Aug 28
• Novo Nordisk expanded its pediatric label franchise on September 15, 2026.Sep 17